Zacks Investment Research
19 Jun 2026, 13:40 UTC · 1h ago
Denali to Sell Priority Review Voucher for $195M Cash Boost
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
19 Jun 2026, 13:40 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Denali Therapeutics entered a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $195 million. — A significant non-dilutive cash infusion strengthens the balance sheet and extends the company's runway without diluting existing shareholders.
+0.60The FDA granted accelerated approval for Avlayah (tividenofusp alfa-eknm) for the treatment of Hunter syndrome in March 2026. — Product approval provides a commercial path and validates the company's proprietary blood-brain barrier transport technology.
+0.50Denali and partner Biogen reported disappointing top-line results from a mid-stage study evaluating BIIB122. — Negative clinical trial data for a key candidate increases the risk profile of the remaining pipeline and hurts investor confidence in specific targets.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is receiving a $195 million non-dilutive capital infusion from a PRV sale and has seen significant growth prospects following FDA approval of Avlayah.
The company and its partner announced disappointing top-line results from a mid-stage study evaluating BIIB122.
[mutual] Denali and partner Biogen collaborated on a mid-stage study for BIIB122.
[mutual] Denali has collaborated with Sanofi to develop drug candidates.
[mutual] Denali has collaborated with Takeda to develop drug candidates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
CNBC
10h ago
